Interim analysis of a postauthorization safety study on long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in primary immunodeficiency disease in Europe

P. M. Ellerbroek,P. van Paassen,L. Hanitsch,A. Plebani, R. E. Schmidt,P. M. van Hagen, P. Wang, K. Fielhauer, H. Leibl, L. Yel

SWISS MEDICAL WEEKLY（2019）

Cited 0|Views2

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined